OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AMSL.CM55

Asiri Surgical Hospital PLC

Healthcare Facilities & ServicesVerified

Asiri Surgical Hospital PLC maintains a debt-to-equity ratio of 0.5, indicating a balanced capital structure with moderate leverage. The company's liquidity position is characterized as medium, with a current ratio of 1.5, suggesting it can cover short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 2.26% and a return on assets (ROA) of 1.08%, both below the industry median for healthcare facilities and services. These figures suggest the company is underperforming in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single geographic market, Sri Lanka, with no disclosed international operations. This geographic concentration increases exposure to local economic and regulatory risks. No segment-specific revenue breakdown is available, limiting visibility into the performance of different service lines. Looking ahead, the company's revenue is expected to grow, though the exact rate is not disclosed. Historical revenue of LKR 1.7 billion provides a baseline for future performance. The company's free cash flow of LKR 242.99 million indicates some capacity for reinvestment or shareholder returns, though capital expenditures of LKR 39.81 million suggest ongoing investment in infrastructure. The company's risk profile is marked by medium liquidity risk and low dilution potential. The negative net cash position after debt is a key flag, but the absence of recent dilutive events and a stable share count suggest no immediate pressure on equity. No recent filings or transcripts are available to provide additional context on strategic or operational developments.

30-day price · AMSL.CM+8.80 (+55.7%)
Low$14.50High$28.10Close$24.60As of12 May, 00:00 UTC
Profile
CompanyAsiri Surgical Hospital PLC
TickerAMSL.CM
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Asiri Surgical Hospital PLC operates in the healthcare facilities and services industry, providing surgical and related medical services to patients in Sri Lanka.

Classification. Asiri Surgical Hospital PLC is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Asiri Surgical Hospital PLC maintains a debt-to-equity ratio of 0.5, indicating a balanced capital structure with moderate leverage. The company's liquidity position is characterized as medium, with a current ratio of 1.5, suggesting it can cover short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 2.26% and a return on assets (ROA) of 1.08%, both below the industry median for healthcare facilities and services. These figures suggest the company is underperforming in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single geographic market, Sri Lanka, with no disclosed international operations. This geographic concentration increases exposure to local economic and regulatory risks. No segment-specific revenue breakdown is available, limiting visibility into the performance of different service lines. Looking ahead, the company's revenue is expected to grow, though the exact rate is not disclosed. Historical revenue of LKR 1.7 billion provides a baseline for future performance. The company's free cash flow of LKR 242.99 million indicates some capacity for reinvestment or shareholder returns, though capital expenditures of LKR 39.81 million suggest ongoing investment in infrastructure. The company's risk profile is marked by medium liquidity risk and low dilution potential. The negative net cash position after debt is a key flag, but the absence of recent dilutive events and a stable share count suggest no immediate pressure on equity. No recent filings or transcripts are available to provide additional context on strategic or operational developments.
Key takeaways
  • Asiri Surgical Hospital PLC maintains a balanced capital structure with a debt-to-equity ratio of 0.5.
  • The company's ROE and ROA are below industry medians, indicating suboptimal capital and asset efficiency.
  • Revenue is concentrated in Sri Lanka, increasing exposure to local economic and regulatory risks.
  • Free cash flow of LKR 242.99 million provides some flexibility for reinvestment or shareholder returns.
  • The company's liquidity position is medium, with a current ratio of 1.5 and a negative net cash position after debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyLKR
Revenue$1.70B
Gross profit$682.7M
Operating income$269.3M
Net income$152.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$197.9M
CapEx-$39.8M
Free cash flow$243.0M
Total assets$14.21B
Total liabilities$7.43B
Total equity$6.77B
Cash & equivalents$737.3M
Long-term debt$3.41B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$5.84B$1.46B$1.18B$665.6M
FY-3$5.63B$1.00B$555.1M$191.8M
FY-2$6.62B$484.9M$31.6M$387.8M
FY-1$7.18B$672.2M$265.7M$400.6M
FY0$7.72B$1.31B$822.9M$857.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$10.63B$5.15B$315.7M
FY-3$13.25B$5.98B$269.0M
FY-2$13.05B$6.19B$461.1M
FY-1$14.44B$6.47B$336.4M
FY0$16.32B$7.30B$649.1M
PeriodOCFCapExFCFSBC
FY-4$1.13B-$265.3M$665.6M
FY-3$570.6M-$322.3M$191.8M
FY-2$245.8M-$146.9M$387.8M
FY-1-$122.7M-$312.4M$400.6M
FY0$368.4M-$520.8M$857.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.70B$269.3M$152.9M$243.0M
FQ-6$1.84B$268.8M$153.2M$211.0M
FQ-5$1.81B$193.4M$65.7M-$95.4M
FQ-4$1.84B-$29.8M-$106.1M$42.0M
FQ-3$1.90B$327.8M$170.0M$291.2M
FQ-2$1.99B$359.4M$200.0M$32.0M
FQ-1$1.96B$340.0M$251.4M$252.6M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
PeriodAssetsEquityCashDebt
FQ-7$14.21B$6.77B$737.3M
FQ-6$14.88B$6.96B$901.9M
FQ-5$14.96B$7.04B$465.5M
FQ-4$14.44B$6.47B$336.4M
FQ-3$16.21B$7.42B$522.9M
FQ-2$15.52B$6.86B$426.5M
FQ-1$16.43B$7.09B$518.4M
PeriodOCFCapExFCFSBC
FQ-7-$197.9M-$39.8M$243.0M
FQ-6-$238.4M-$108.5M$211.0M
FQ-5-$19.5M-$243.1M-$95.4M
FQ-4-$122.7M-$312.4M$42.0M
FQ-3-$222.9M-$12.8M$291.2M
FQ-2$214.0M-$316.2M$32.0M
FQ-1$670.5M-$449.6M$252.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$6.77B
Net cash-$2.67B
Current ratio1.5
Debt/Equity0.5
ROA1.1%
ROE2.3%
Cash conversion-1.3%
CapEx/Revenue-2.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricAMSL.CMActivity
Op margin15.9%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin9.0%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin40.2%45.5% medp25 31.1% · p75 62.9%below median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-2.4%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity50.0%25.0% medp25 3.8% · p75 63.3%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:13 UTC#ae36e740
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 08:47 UTCJob: bb627f10